Phenotype | Cases numbers refer to 'any prostate cancer'. Of those, 716 had aggressive prostate cancer (Gleason score ≥7, PSA ≥ 10 ng/mL, T3–T4 stage, nodal metastases, or distant metastases) and 57 had fatal prostate cancer. Death was determined by the investigators of each contributing study using cancer registries and/or medical records. Age shows the age of diagnosis. 1028 individuals had a family history of prostate cancer (≥1 first degree relative affected). |
Sample Ancestry | Asian unspecified, NR |
Total number | 2,382 individuals |
Detailed numbers |
1,197 cases (50.25%)
1,185 controls
100.0% Male samples
|
Age of Study Participants |
|
Number of Cohort(s) | 60 |
Cohort Short Name | Cohort Full Name | Previous/other/additional names (e.g. sub-cohorts) |
---|---|---|
Aarhus | Aarhus | — |
AHS | Agricultural Health Study | — |
ATBC | Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study | — |
BioVU | BioVU, the Vanderbilt DNA Databank project | — |
CCI | CCI | — |
CeRePP | French Prostate Cancer Case-Control Study | — |
CHIPGECS | Chinese Prostate Cancer Genetic and Environmental Correlation Study | — |
COH | City of Hope Cancer Centre | — |
CONOR | Cohort of Adults in Norway | — |
COSM | Cohort of Swedish Men | — |
CPCS | Copenhagen Prostate Cancer Study | — |
CPDR | Center for Prostate Disease Research | — |
EPIC | European Prospective Investigation into Cancer | — |
EPICAP | Epidemiology of Prostate Cancer | — |
ERSPC | European Randomised Study of Screening for Prostate Cancer | — |
ESTHER | Epidemiological investigations on chances of preventing, recognizing early and optimally treating chronic diseases in an elderly population / Epidemiologische Studie zu Chancen der Verhütung, Früherkennung und optimierten Therapie chronischer Erkrankungen in der älteren Bevölkerung, Verlauf der diagnotischen Abklärung bei Krebspatienten | Epidemiological investigations of the chances of preventing, recognizing early and optimally treating chronic diseases in an elderly population (ESTHER_ELDERLY), Epidemiologische Studie zu Chancen der Verhütung, Früherkennung und optimierten Therapie chronischer Erkrankungen in der älteren Bevölkerung, Verlauf der diagnotischen Abklärung bei Krebspatienten (ESTHER-VERDI) |
FHCRC | Fred Hutchinson Cancer Research Center, Seattle US | — |
Gene-PARE | Genetic Predictors of Adverse Radiotherapy Effects | — |
HPFS | Health Professional Follow-up Study | — |
IMPACT | Identification of Men with a genetic predisposition to ProstAte Cancer | — |
IPO-Porto | IPO-Porto Prostate Cancer study | — |
KARUPROSTATE | French West Indies Prostate cancer Study (from Karukera, the original Caribbean name of Guadeloupe) | — |
KULEUVEN | Katholieke Universiteit Leuven | — |
LAAPC | Los Angeles Study of Aggressive Prostate Cancer | — |
MCCS | Melbourne Collaborative Cohort Study | — |
MCC-Spain | Multi-case Control Study, Spain | — |
MDACCS | MD Anderson Cancer Center Study | — |
MEC | Multiethnic Cohort Study of Diet and Health | — |
MOFFITT | The Moffitt Group | — |
NMHS | Nashville Men's Health Study | — |
PASS | Prostate Active Surveillance Study | — |
PCaP | North Carolina-Louisiana Prostate Cancer Project Consortium | — |
PCMUS | Prostate Cancer study Medical University Sofia | — |
PCPT | Prostate Cancer Prevention Trial | SWOG-PCPT |
PHS | Physicians Health Study | — |
PLCO | Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial | — |
PRAGGA | Prostate Cancer Genetics in Galacia | — |
PROCAP | PROgression in Cancer of the Prostate | — |
PROFILE | Genetic Prostate cancer risk stratification for targeted screening | — |
PROGReSS_PrCa | Prostate Cancer Group, Santiago, Spain | — |
ProMPT | Prostate cancer : Mechanisms of progression and Treatment (UK) | — |
ProtecT | Prostate testing for cancer and Treatment study | — |
PROtEuS | Prostate Cancer and Environment Study | — |
QLD | Queensland Study | — |
RAPPER | Radiogenomics: Assessment of Polymorphisms for Predicting the effects of radiotherapy | — |
SABOR | San Antonio Center of Biomarkers of Risk for Prostate Cancer | — |
SCCS | NBHS/Southern Community Cohort | — |
SCPCS | South Carolina Prostate Cancer Study | — |
SEARCH | Study of Epidemiology and Risk Factors in Cancer Heredity | — |
SELECT | Selenium and Vitamin E Cancer Prevention Trial | — |
SFPCS | San Francisco Prostate Cancer Study | — |
SNP_Prostate_Ghent | SNP Prostate Ghent (Belgium) | — |
SPAG | Serum Proteomic analysis for biomarkers of Aggressive prostate disease in the Guernsey population | — |
STHM | The Stockholm Study | STHM1, STHM2, Stockholm-1, Stockholm-2, STHLM, STHLM2 |
TAMPERE | Tampere University Hospital | — |
Toronto | Toronto | — |
UKGPCS | UK Genetic Prostate Cancer Study | — |
ULM | Center of Excellence-Baden-Wuerttemberg Type 2 Diabetes Cohort | — |
WFPCS | Wake Forest Prostate Cancer Study | — |
WUGS | Washington University Genetics Study | — |